HOLX - Hologic EPS revenue drop in FQ4 but beat expectations as FY 2022 guidance issued

Although Hologic (NASDAQ:HOLX) reported fiscal year 2021 Q4 revenue and EPS that was considerably lower than in the prior-year period, it was enough to beat Street expectations. Revenue of ~1.32B was ~2.3% lower than in FQ4 2020. While total diagnostics revenues declined 11% to $836.8M, total breast health revenue increased 15.6% to $334.2M. On a GAAP basis, diluted EPS was $1.28, a nearly 32% drop from the same period a year ago. Looking ahead to fiscal year 2022, Hologic sees revenue of $3.75B - $4B ($3.93B consensus), nd non-GAAP EPS: $3.55- $3.85 ($3.69 consensus). Find out more about Hologic's recent acquistion of Bolder Surgical.

For further details see:

Hologic EPS, revenue drop in FQ4 but beat expectations as FY 2022 guidance issued